SCHEMBL26638883

SCHEMBL26638883

COC(=O)c1sc(C=O)nc1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.48
NPC1 O15118 5/20 0.48
HPGD P15428 4/20 0.48
SMN1; SMN2 Q16637 6/20 0.44
ALDH1A1 P00352 4/20 0.44
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 2/20 0.42
KMT2A Q03164 4/20 0.41
MAPT P10636 4/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25256968 0.83 ALDH1A1 (0.55) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL26639212 0.81 RAB9A (0.44) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL25297051 0.79 TSHR (0.45) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL10049913 0.77 NPC1 (0.54) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL560326 0.76 RAB9A (0.51) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL19981322 0.74 HPGD (0.63) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL276275 0.74 ALDH1A1 (0.62) RAB9ANPC1HPGDALDH1A1POLB
SCHEMBL7023549 0.74 RAB9A (0.50) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL160229 0.71 CNR1 (0.50) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1
SCHEMBL13542752 0.71 RAB9A (0.48) RAB9ANPC1HPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 US disclosed
EP-4522604-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS Merck Sharp & Dohme LLC (US) 2025-03-19 EP disclosed
US-20230365551-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2023-11-16 US disclosed
WO-2023220225-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS MERCK SHARP & DOHME LLC (US) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365551-A1 INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS NHERF1, ACE, METAP1 RAB9A 217/4885NPC1 714/4885HPGD 912/4885
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus NHERF1, ZC3HAV1, SARS1 RAB9A 412/4885NPC1 125/4885HPGD 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.